Render Target: STATIC
Render Timestamp: 2025-02-07T11:54:01.982Z
Commit: 1bba917eefc12d62e72a522121e2774ffbd0ee36
XML generation date: 2024-11-18 16:03:13.414
Product last modified at: 2025-01-01T09:02:11.802Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

COL7A1 (F4Q8A) Rabbit mAb #81703

Filter:
  • WB
  • IF

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 330
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunofluorescence (Immunocytochemistry) 1:3200 - 1:12800

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    COL7A1 (F4Q8A) Rabbit mAb recognizes endogenous levels of total COL7A1 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus region of human COL7A1 protein.

    Background

    Type VII collagen is a collagen family protein encoded by the COL7A1 gene. Collagen VII is formed by intertwining three COL7A1 chains to function as an anchoring fibril (1). The anchoring fibril is localized in the basement membrane and crucial for dermal-epidermal basement membrane adhesion through the interaction of the N-terminal NC1 domain of COL7A1 with collagen IV, laminin 332, and collagen I (2-5). Mutations of COL7A1 prevent type VII collagen secretion or interaction with other ECM molecules, lead to anchoring fibril deficiencies in the dermal-epidermal basement membrane, and result in skin blistering (Dystrophic Epidermolysis Bullosa) and poor wound healing (6-8). Type VII collagen deficiency also results in the oncogenesis of cutaneous squamous cell carcinoma through increasing TGF-β signaling and abnormal angiogenesis (9,10).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.